BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31030682)

  • 1. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
    Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
    Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
    Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
    Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
    Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
    Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
    Pandit B; Sarkozy A; Pennacchio LA; Carta C; Oishi K; Martinelli S; Pogna EA; Schackwitz W; Ustaszewska A; Landstrom A; Bos JM; Ommen SR; Esposito G; Lepri F; Faul C; Mundel P; López Siguero JP; Tenconi R; Selicorni A; Rossi C; Mazzanti L; Torrente I; Marino B; Digilio MC; Zampino G; Ackerman MJ; Dallapiccola B; Tartaglia M; Gelb BD
    Nat Genet; 2007 Aug; 39(8):1007-12. PubMed ID: 17603483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal pulmonary arterial hypertension and Noonan syndrome: two fatal cases with a specific RAF1 mutation.
    Hopper RK; Feinstein JA; Manning MA; Benitz W; Hudgins L
    Am J Med Genet A; 2015 Apr; 167A(4):882-5. PubMed ID: 25706034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted/exome sequencing identified mutations in ten Chinese patients diagnosed with Noonan syndrome and related disorders.
    Xu S; Fan Y; Sun Y; Wang L; Gu X; Yu Y
    BMC Med Genomics; 2017 Oct; 10(1):62. PubMed ID: 29084544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
    Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
    Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK Inhibition in a Newborn with
    Mussa A; Carli D; Giorgio E; Villar AM; Cardaropoli S; Carbonara C; Campagnoli MF; Galletto P; Palumbo M; Olivieri S; Isella C; Andelfinger G; Tartaglia M; Botta G; Brusco A; Medico E; Ferrero GB
    Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
    Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
    J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
    Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
    Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RAF1 mutation leading to hypertrophic cardiomyopathy in a Chinese family with a history of sudden cardiac death: A diagnostic insight into Noonan syndrome.
    Zheng J; Peng L; Cheng R; Li Z; Xie J; Huang E; Cheng J; Zhao Q
    Mol Genet Genomic Med; 2024 Jan; 12(1):e2290. PubMed ID: 37787490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease in Noonan syndrome.
    Pierpont ME; Digilio MC
    Curr Opin Pediatr; 2018 Oct; 30(5):601-608. PubMed ID: 30024444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
    Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
    Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
    Ko JM; Kim JM; Kim GH; Yoo HW
    J Hum Genet; 2008; 53(11-12):999-1006. PubMed ID: 19020799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome.
    Passariello CL; Martinez EC; Thakur H; Cesareo M; Li J; Kapiloff MS
    J Mol Cell Cardiol; 2016 Apr; 93():98-105. PubMed ID: 26940993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene mutation and clinical phenotype analysis of patients with Noonan syndrome and hypertrophic cardiomyopathy].
    Liu XH; Ding WW; Han L; Liu XR; Xiao YY; Yang J; Mo Y
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):780-784. PubMed ID: 29050118
    [No Abstract]   [Full Text] [Related]  

  • 17. PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
    Pelc M; Ciara E; Jezela-Stanek A; Krajewska-Walasek M
    Genet Couns; 2016; 27(3):325-333. PubMed ID: 30204961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.
    Yagasaki H; Nakane T; Hasebe Y; Watanabe A; Kise H; Toda T; Koizumi K; Hoshiai M; Sugita K
    Am J Med Genet A; 2015 Dec; 167A(12):3144-7. PubMed ID: 26286251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noonan syndrome associated with both a new Jnk-activating familial SOS1 and a de novo RAF1 mutations.
    Longoni M; Moncini S; Cisternino M; Morella IM; Ferraiuolo S; Russo S; Mannarino S; Brazzelli V; Coi P; Zippel R; Venturin M; Riva P
    Am J Med Genet A; 2010 Sep; 152A(9):2176-84. PubMed ID: 20683980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.
    Levin MD; Saitta SC; Gripp KW; Wenger TL; Ganesh J; Kalish JM; Epstein MR; Smith R; Czosek RJ; Ware SM; Goldenberg P; Myers A; Chatfield KC; Gillespie MJ; Zackai EH; Lin AE
    Am J Med Genet A; 2018 Aug; 176(8):1711-1722. PubMed ID: 30055033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.